Use Of Fragmin In Hemodialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

Also called NCT01879618

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 152 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01879618
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01879618. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2016-03 (actual). Results posted on 2016-12-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use Of Fragmin In Hemodialysis
Condition
Chronic Renal Failure
Intervention (Drug)
Fragmin
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01879618
Content hash
c586f0d0ff19652cac1411eec2026f5cf3379393db12f784e434413ab0d85a07